GHRP-2 vs ANP (Atrial Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
GHRP-2
Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.
Full details →ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Side-by-Side Comparison
| Aspect | GHRP-2 | ANP (Atrial Natriuretic Peptide) |
|---|---|---|
| Mechanism | Binds to the ghrelin receptor (GHS-R) to stimulate GH release from the pituitary. Also has some direct effects on the hypothalamus. Causes less appetite increase than GHRP-6. | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily. Often stacked with GHRH peptides for enhanced GH release. | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. |
| Administration | Subcutaneous injection on an empty stomach. Can be used at bedtime to enhance natural GH pulse during sleep. | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. |
| Side Effects | Moderate hunger increase, water retention, potential prolactin and cortisol elevation (less than GHRP-6), tingling sensations. | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. |
| Best For |